Yazdian Kashani Sepideh, Afzalian Amir, Shirinichi Farbod, Keshavarz Moraveji Mostafa
Department of Chemical Engineering, Amirkabir University of Technology (Tehran Polytechnic) 1591634311 Tehran Iran
RSC Adv. 2020 Dec 23;11(1):229-249. doi: 10.1039/d0ra08607j. eCollection 2020 Dec 21.
Core-shell drug-carrier particles are known for their unique features. Due to the combination of superior properties not exhibited by the individual components, core-shell particles have gained a lot of interest. The structures could integrate core and shell characteristics and properties. These particles were designed for controlled drug release in the desired location. Therefore, the side effects would be minimized. So, these particles' advantages have led to the introduction of new methods and ideas for their fabrication. In the past few years, the generation of drug carrier core-shell particles in microfluidic chips has attracted much attention. This method makes it possible to produce particles at nanometer and micrometer levels of the same shape and size; it usually costs less than other methods. The other advantages of using microfluidic techniques compared to conventional bulk methods are integration capability, reproducibility, and higher efficiency. These advantages have created a positive outlook on this approach. This review gives an overview of the various fluidic concepts that are used to generate microparticles or nanoparticles. Also, an overview of traditional and more recent microfluidic devices and their design and structure for the generation of core-shell particles is given. The unique benefits of the microfluidic technique for core-shell drug carrier particle generation are demonstrated.
核壳药物载体颗粒因其独特的特性而闻名。由于单个组分所不具备的优异性能的结合,核壳颗粒引起了广泛关注。这些结构可以整合核和壳的特征与性质。这些颗粒被设计用于在期望的位置实现药物的控释。因此,副作用将被最小化。所以,这些颗粒的优势促使了其制备新方法和新思路的引入。在过去几年中,在微流控芯片中生成药物载体核壳颗粒受到了广泛关注。这种方法能够生产出具有相同形状和尺寸的纳米级和微米级颗粒;其成本通常低于其他方法。与传统的批量方法相比,使用微流控技术的其他优势包括集成能力、可重复性和更高的效率。这些优势为这种方法带来了积极的前景。本综述概述了用于生成微粒或纳米颗粒的各种流体概念。此外,还概述了传统的和最新的微流控装置及其用于生成核壳颗粒的设计和结构。展示了微流控技术在生成核壳药物载体颗粒方面的独特优势。